TWSTTwist Bioscience Corporation
$159.83+473% 1Y
$159.83
$25.4552 weeks$204.94
TWST in its own filings
Nothing in TWST's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
139
Events found in the filings · across 1,623 filings · the record starts in 2018
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 19, 2026
Most recent filing · Form 8-K
- Record starts
- Mar 9, 2018
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 13, 2026
- Change in certifying accountanthistorical
- 2022-03-09
- SEC comment-letter activity16 occurrences
- 2026-03-05
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 19, 2026Pursuant to that certain Registration Rights Agreement dated February 11, 2026 by and between Twist Bioscience Corporation (the “Company”) and Invenra Inc. (“Invenra”), the Company is filing a prospectus supplement to register the resale of shares issuable pursuant to that certain Stock Purchase Agreement dated …Other event · Form 8-K
- Aug 5, 2026On August 4, 2026, Twist Bioscience Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, William Blair & Company, L.L.C., Leerink Partners LLC, and Guggenheim Securities, LLC, as representatives of the several underwriters named therein …Material agreement entered · Form 8-K
- Aug 3, 2026Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results.Earnings release · press release
- May 4, 2026Twist Bioscience Reports Fiscal Second Quarter 2026 Financial Results.Earnings release · press release
- Feb 2, 2026Twist Bioscience Reports Fiscal First Quarter 2026 Financial Results.Earnings release · press release
- Nov 14, 2025Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2025 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks
Diagnostics & Research
Ranks #20 of 21 by RyuScore